Detalles de la búsqueda
1.
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Ann Intern Med
; 175(9): 1221-1229, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35939812
2.
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
J Viral Hepat
; 26(3): 329-336, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30412325
3.
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
J Viral Hepat
; 26(6): 675-684, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30739366
4.
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
J Viral Hepat
; 26(9): 1127-1138, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31108015
5.
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Hepatology
; 67(6): 2113-2126, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29473975
6.
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Gastroenterology
; 152(6): 1372-1382.e2, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28193518
7.
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
Gastroenterology
; 152(1): 164-175.e4, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27720838
8.
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Am J Gastroenterol
; 113(6): 863-871, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29695828
9.
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Hepatology
; 66(3): 736-745, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28256747
10.
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Hepatology
; 65(2): 439-450, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27770561
11.
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.
Hepatology
; 66(6): 1794-1804, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28688129
12.
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Liver Int
; 38(9): 1583-1591, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29461687
13.
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease.
Hepatol Res
; 47(12): 1340-1345, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28334495
14.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med
; 165(9): 625-634, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27537841
15.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Clin Infect Dis
; 62(1): 32-6, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26371152
16.
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
J Hepatol
; 65(6): 1112-1119, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27542322
17.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
Lancet
; 386(10003): 1537-45, 2015 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26456905
18.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467560
19.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467591
20.
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Ann Intern Med
; 163(1): 1-13, 2015 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25909356